Isofol Medical: Scores a win in CC-005 trial
Research Note
2019-05-09
06:09
Isofol reported encouraging results from an extension study of the phase I/IIa trial CC-005, where arfolitixorin is evaluated as part of the first-line treatment regimen in patients with metastatic colorectal cancer (mCRC).
AN
Arvid Necander
Disclosures and disclaimers